Led · Series B · Jan 2026

Founded in September 2021 and headquartered in Beijing, Yuewei Medical builds medical devices that target unmet clinical needs in cardiovascular surgery. The company has two self-developed product lines—coronary surgery and critical-care/extracorporeal circulation—covering nearly ten devices, among them an ultrasound vascular flow measurement system, a pulsatile left ventricular assist system and a double-lumen jugular catheter, all described as domestic firsts. Its pipeline also spans AI-driven diagnostics, high-end innovative hardware and import-substitution products, giving it a tiered portfolio from early to late stage. Leveraging acquisition capability, the company plans to expand into a deep-vein thrombosis (DVT) product line by 2025, adding two devices already in registrational clinical trials. Management emphasizes an “clinician-engineer” model that tightly integrates clinical insight with R&D. Though no revenue figures were disclosed, Yuewei reports that its commercial model has already been validated in China’s fragmented cardiovascular surgical market.

Led · Series B · Nov 2025

Founded in 2017 in Shanghai, Rigen Biotech focuses on creating a full-process solution for thyroid nodules and thyroid cancer. Its product matrix includes disposable biopsy needles, multi-gene qPCR and NGS test kits, a thyroglobulin gene assay, and the AI-driven Thyroscan® classifier tailored to the Chinese population. In August 2023 the company secured China’s first Class III registration for a multi-gene thyroid nodule test (BRAF/TERT/CCDC6-RET), and in October 2025 its thyroglobulin mRNA kit entered the NMPA breakthrough review program. Rigen operates a 2,500 m² GMP facility, is ISO13485-certified, and employs more than 200 staff, including five national-level experts. Its products already serve nearly 200 top-tier hospitals across more than 30 provinces, winning wide clinical adoption. Looking ahead, the firm plans to expand into intra-operative therapy and post-operative chronic management while accelerating new product registrations, with the goal of achieving multi-fold revenue growth.

Led · Series C · Jun 2025

QureBio develops bispecific and multispecific antibody and protein therapeutics using proprietary platforms including I2T and T‑cell and NK‑cell engager platforms. Its pipeline includes Q‑1802 (Claudin18.2/PD‑L1 bispecific) with Phase II enrollment nearly complete and preparations for Phase III in China, Q‑1801 (SIRPα/PD‑L1 bispecific) poised to begin clinical studies, and a PD‑1 antibody‑cytokine fusion candidate. The company has regulatory clearances to initiate clinical trials in both China and the United States for multiple candidates. QureBio was founded in 2017 and is based in Shanghai. It has established collaborations with BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific to co‑develop therapies. The recent financing will be used to accelerate clinical trials and advance its core pipeline globally. QureBio is dedicated to the development of innovative antibody drugs. The company is invested in and incubated by Viva BioInnovator. In December 2021 QureBio announced it had completed nearly 200 Million RMB in a Series B financing. The Series B round was led by BOCOM International Holdings. Other participants in the round included Guoshun Investment, Oriza Holdings, Lihe Hongxin Venture Investment, Tianfu Sanjiang Capital, Spinnotec and Longmen Capital.

Led · Equity · Jun 2024

CATUG Biotechnology (楷拓生物) concentrates on technology development and application for gene therapy and nucleic acid therapeutics. The company positions itself as a full‑industry‑chain, one‑stop CDMO offering services across R&D, clinical application, and industrialization. It focuses on building and upgrading full‑process CRDMO service capabilities for nucleic‑acid drugs. CATUG recently completed a new financing round of nearly RMB 100 million. The proceeds will be used to expand its overseas business and to upgrade its end‑to‑end CRDMO service capabilities. The company aims to solidify its core competitiveness on the nucleic‑acid drug technology track.

Led · Series A · May 2023

Founded in February 2021, 凌意生物 operates a leading animal‑model platform to support discovery, development and industrialization of gene therapies. The company focuses on metabolic, CNS and ophthalmic indications and aims to address the shortage of effective animal models for single‑gene genetic diseases. It is developing an FIC gene therapy pipeline and has assembled an international‑level discovery, development and commercialization team. Management emphasizes clinical‑need driven innovation, differentiated indications and global patent布局 and clinical progress according to investor commentary in the article. Following the new financing the company plans to establish its headquarters in Qianwan Biopark, Xiaoshan District, Hangzhou and will use proceeds to accelerate pipeline development and technology platform construction. Haoyue Capital served as exclusive financial advisor to the transaction. Lingyi Biotech, founded in February 2021, operates a global-leading rare-disease animal-model functional validation platform. The company focuses on source innovation in gene therapy, concentrating on metabolic, CNS, and ophthalmic genetic rare diseases. It has discovery, development, and industrialization teams with international-level experience in gene therapy and rare-disease R&D. Lingyi builds and validates animal models to address the shortage of effective models in rare-disease research. Its pipeline includes multiple globally leading gene-therapy projects currently in preclinical development. The company says it will continue deep work in gene therapy and aims to develop proprietary gene-therapy products to benefit patients.